Product Description
Gaboxadol (OV101) is a delta-subunit–selective, extrasynaptic GABAA receptor agonist that enhances GABAergic tonic inhibition, providing the rationale for assessment of OV101 as a potential targeted treatment of FXS. No drug is approved in the United States for the treatment of FXS. (Sourced from: https://www.frontiersin.org/articles/10.3389/fphar.2021.757825/full#:~:text=Gaboxadol%20(OV101)%20is%20a%20%CE%B4,for%20the%20treatment%20of%20FXS.)
Mechanisms of Action: GABA Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Ovid
Company Location: Eastern America
Company CEO: Jeremy M. Levin
Additional Commercial Interests: Healx
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Fragile X Syndrome
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06334419 |
NCT06334419 | P2 |
Completed |
Fragile X Syndrome |
2025-05-13 |
50% |
2025-12-24 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/10/2024 |
PubMed |
Extrasynaptic δGABAA receptors mediate resistance to migraine-like phenotype in rats. |
|
04/30/2024 |
PubMed |
Impact of Abl2/Arg deficiency on anxiety and depressive behaviors in mice. |
|
04/08/2024 |
PubMed |
Manipulation of α4βδ GABAA receptors alters synaptic pruning in layer 3 prelimbic prefrontal cortex and impairs temporal order recognition: Implications for schizophrenia and autism. |
|
09/07/2023 |
News Article |
Fragile X Syndrome Market Revenue Report with Forecast to 2031 |
|
03/04/2022 |
News Article |
Ovid Therapeutics to Participate at the Cowen 42nd Annual Health Care Conference |
|
02/08/2022 |
News Article |
Healx and Ovid Therapeutics to Enter Strategic Partnership |
|
09/03/2021 |
News Article |
Blackhawk Growth Closes Investment in Psychedelic and Wellness Company MindBio Therapeutics Pty Ltd. |